Development and optimization of chemically stable lipid microspheres containing flunarizine Improving the stability of flunarizine

Drug Development and Industrial Pharmacy

Volumn 35, Issue 6, 2009, Pages 738-745

  Chi, Na ^a   Tang, Xing ^a   Xu, Hui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Lipid microspheres

Indexed keywords

DRUG VEHICLE; FLUNARIZINE; GLYCEROL; LIPID; LONG CHAIN TRIACYLGLYCEROL; MEDIUM CHAIN TRIACYLGLYCEROL; MICROSPHERE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; TOCOPHEROL;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; PH; SOYBEAN; TEMPERATURE ACCLIMATIZATION;

ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; FLUNARIZINE; HYDROGEN-ION CONCENTRATION; LIPIDS; MICROSPHERES; TEMPERATURE; TIME FACTORS;

EID: 70350597669     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802537893     Document Type: Article

References (25)

1. Busaranon K, Suntornsuk W, Suntornsuk L. (2006). Comparison of UV spectrophotometric method and high performance liquid chromatography for the analysis of flunarizine and its application for the dissolution test. J Pharm Biomed Anal, 41:158-164
2. Belforte JE, Magarinos-Azcone C, Armando I, Buno W, Pazo JH. (2001). Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. Parkinsonism Relat Disord, 8:33-40.
3. Andersson KE, Vinge E. (1990). ?-Adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs, 39:355-373
4. Marin MT, Margarit MV, Salcedo GE. (2002). Characterization and solubility study of solid dispersions of flunarizine and polyvinylpyrrolidone. Farmaco, 57:723-727
5. Uslu B, Yilmaz N, Erk N, Ozkan SA, Senturk Z, Briyol L. (1999). The study of the voltammetric behaviour of flunarizine. J Pharm Biomed Anal, 21(1):215-220
6. Venkateswarlu V, Patlolla RR. (2001). Lipid microspheres as drug delivery systems. Ind J Pharm Sci, 63:450-458
7. Dan LW. (2005). Evolution of parenteral lipid emulsions. Clin Nutr Suppl, 1:5-7.
8. Jumaa M, Muller BW. (2002). Parenteral emulsions stabilized with a mixture of phospholipids and PEG-660-12-hydroxy-stearate: Evaluation of accelerated and long-term stability. Eur J Pharm Biopharm, 54:207-212
9. Chansiri G, Lyons RT, Patel MV, Hem SL. (1999). Effect of surface charge on the stability of oil/water emulsions during steam sterilization. J Pharm Sci, 88:454-458
10. Bakan DA, Longino MA, Weichert JP, Counsell RE. (1996). Physicochemical characterization of a synthetic lipid emulsion for hepatocyte-selective delivery of lipophilic compounds: Application to polyiodinated triglycerides as contrast agents for computed tomography. J Pharm Sci, 85:908-914
11. Müller RH, Schmidt S, Buttle I, Akkar A, Schmitt J, Brömer S. (2004). SolEmuls® -novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm, 269:293-302.
12. Cui G, Wang L, Davis PJ, Kara M, Liu H. (2006). Preparation and physical characterization of a novel marine oil emulsion as a potential new formulation vehicle for lipid soluble drugs. Int J Pharm, 325:180-185
13. Teagarden DL, Anderson BD, Petre WJ. (1996). The distribution and chemical kinetics of prostaglandin E, in lipid emulsions. Adv Drug Deliv Rev, 20:155-164
14. Laguerre M, Lecomte J, Villeneuve P. (2007). Evaluation of the ability of antioxidants to counteract lipid oxidation: Existing methods, new trends and challenges. Prog Lipid Res, 46:244-282
15. Becker EM, Nissen LR, Skibsted LH. (2004). Antioxidant evaluation protocols: Food quality or health effects. Eur Food Res Technol, 219:561-571
16. Ferezou J, Lai NT, Leray C, Hajri T, Frey A, Cabaret Y, et al. (1994). Lipid composition and structure of commercial parenteral emulsions. Biochim Biophys Acta, 1213:149-158
17. Wang LX, He HB, Tang X, Shao RY, Chen DW. (2006). A less irritant norcantharidin lipid microspheres: Formulation and drug distribution. Int J Pharm, 323:161-167
18. Washington C. (1996). Stability of lipid emulsions for drug delivery. Adv Drug Deliv Rev, 20, 131-145
19. Lovell MW, Johnson HW, Hui HW, Cannon JB, Gupta PK, Hsu CC. (1994). Less painful emulsion formulations for intravenous administration of clarithromycin. Int J Pharmaceut, 109: 45-57.
20. Tong LM, Sasaki S, McClements DJ, Decker EA. (2000). Mechanisms of the antioxidant activity of a high molecular weight fraction of whey. J Agric Food Chem, 48:1473-1478
21. Viljanen K, Kylli P, Hubbermann EM, Schwarz K, Heinonen M. (2005). Anthocyanin antioxidant activity and partition behavior in whey protein emulsion. J Agric Food Chem, 53:2022-2027
22. Maia AM, Baby AR, Pinto CA, Yasaka WJ, Suenaga E, Kaneko TM, Velasco MV. (2006). Influence of sodium metabisulfite and glutathione on the stability of vitamin C in O/W emulsion and extemporaneous aqueous gel. Int J Pharm, 322:130-135
23. Mei LY, Decker EA, McClements DJ. (1998). Evidence of iron association with emulsion droplets and its impact on lipid oxidation. J Agric Food Chem, 46:5072-5077
24. Mahoney JR, Graf E. (1986). Role of alpha-tocopherol, ascorbic acid, citric acid and EDTA as oxidants in a model system. J Food Sci, 51:1293-1296
25. Grit M, Crommelin DJ. (1993). Chemical stability of liposomes: Implications for 498 their physical stability. Chem Phys Lipids, 6:3-18.